SLC25A5, solute carrier family 25 member 5, 292

N. diseases: 29; N. variants: 0
Disease: Primary malignant neoplasm ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 Biomarker group BEFREE ANT2 can be used as a marker of dedifferentiated pathology and aggressiveness of cancer. 30225759 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 Biomarker group BEFREE ANT2 induced the formation of cancer-initiating cell (CIC) phenotypes and promoted metastasis-associated traits in the Huh7 cells. 28350139 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 Biomarker group BEFREE These findings suggest that ANT2 overexpression contributes to EGFR-TKI resistance in NSCLC and that ANT2 targeting may be considered a novel strategy for overcoming this resistance.Mol Cancer Ther; 15(6); 1387-96.©2016 AACR. 26883272 2016
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 Biomarker group BEFREE ANT2 suppression by shRNA might be exploited to overcome TRAIL-resistance in cancer. 20875141 2010
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 Biomarker group BEFREE These data provide the first argument for the involvement of the ANT2 protein in glycolytic ATP uptake in cancer cell mitochondria and suggest a possible ANT2 antisense strategy for cancer therapy. 8688152 1996